Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP01 Anti-IgE Immunotherapy in Allergic Patients
NCT00439621Phase 2Completed
- Sponsor
- Resistentia Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of RP01 in IgE-mediated allergy, sponsored by Resistentia Pharmaceuticals. Started Feb 2007; status: completed.
02
Drugs
RP01
03
Conditions
IgE-mediated allergy
Beyond the preview
Go deeper on NCT00439621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439621.